Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)
A phase 2 trial of Pimicotinib in tenosynovial giant cell tumour, run by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, now recruiting.
Overview
Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) is a phase 2 interventional study registered as NCT07499362 by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, with 20 participants planned, started 2026-03-26 and due to reach its primary completion in 2029-11-22. Interventions recorded: Pimicotinib.
Similar pages
not linked directly; found by shared links- TrialStudy of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
- TrialA Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
- TreatmentEmactuzumab
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.